000107718312/312021Q1FALSEneo:AccountingStandardsUpdate202006Member0.01511720.027519800010771832021-01-012021-03-31xbrli:shares00010771832021-05-04iso4217:USD00010771832021-03-3100010771832020-12-31iso4217:USDxbrli:shares0001077183neo:ClinicalServicesMember2021-01-012021-03-310001077183neo:ClinicalServicesMember2020-01-012020-03-310001077183neo:PharmaServicesMember2021-01-012021-03-310001077183neo:PharmaServicesMember2020-01-012020-03-3100010771832020-01-012020-03-310001077183us-gaap:CommonStockMember2019-12-310001077183us-gaap:AdditionalPaidInCapitalMember2019-12-310001077183us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001077183us-gaap:RetainedEarningsMember2019-12-3100010771832019-12-310001077183us-gaap:CommonStockMember2020-01-012020-03-310001077183us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001077183us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001077183us-gaap:RetainedEarningsMember2020-01-012020-03-310001077183us-gaap:CommonStockMember2020-03-310001077183us-gaap:AdditionalPaidInCapitalMember2020-03-310001077183us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001077183us-gaap:RetainedEarningsMember2020-03-3100010771832020-03-310001077183us-gaap:CommonStockMember2020-12-310001077183us-gaap:AdditionalPaidInCapitalMember2020-12-310001077183us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001077183us-gaap:RetainedEarningsMember2020-12-310001077183srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2020-12-310001077183srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2020-12-310001077183srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-12-310001077183us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001077183us-gaap:CommonStockMember2021-01-012021-03-310001077183us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001077183us-gaap:RetainedEarningsMember2021-01-012021-03-310001077183us-gaap:CommonStockMember2021-03-310001077183us-gaap:AdditionalPaidInCapitalMember2021-03-310001077183us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001077183us-gaap:RetainedEarningsMember2021-03-3100010771832020-01-012020-12-310001077183srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-01-010001077183us-gaap:ForeignCountryMember2020-12-310001077183us-gaap:ForeignCountryMember2021-03-31xbrli:pure0001077183us-gaap:ConvertibleDebtMemberneo:OnePointTwoFivePercentConvertibleSeniorNotesMember2021-03-310001077183srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2021-01-010001077183us-gaap:USTreasurySecuritiesMember2021-03-310001077183us-gaap:CommercialPaperMember2021-03-310001077183us-gaap:AssetBackedSecuritiesMember2021-03-310001077183us-gaap:CorporateBondSecuritiesMember2021-03-310001077183us-gaap:USTreasurySecuritiesMember2020-12-310001077183us-gaap:CommercialPaperMember2020-12-310001077183us-gaap:AssetBackedSecuritiesMember2020-12-310001077183us-gaap:CorporateBondSecuritiesMember2020-12-310001077183us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-03-310001077183us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-03-310001077183us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-03-310001077183us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-03-310001077183us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2021-03-310001077183us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2021-03-310001077183us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2021-03-310001077183us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2021-03-310001077183us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001077183us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001077183us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001077183us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001077183us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-03-310001077183us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-03-310001077183us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-03-310001077183us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-03-310001077183us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001077183us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001077183us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001077183us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001077183us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001077183us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001077183us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001077183us-gaap:FairValueMeasurementsRecurringMember2021-03-310001077183us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310001077183us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310001077183us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310001077183us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310001077183us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001077183us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001077183us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001077183us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001077183us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-12-310001077183us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-12-310001077183us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-12-310001077183us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-12-310001077183us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2020-12-310001077183us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2020-12-310001077183us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2020-12-310001077183us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2020-12-310001077183us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001077183us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001077183us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001077183us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001077183us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001077183us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001077183us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001077183us-gaap:FairValueMeasurementsRecurringMember2020-12-310001077183stpr:FL2021-01-012021-03-310001077183us-gaap:LeaseholdImprovementsMemberstpr:FL2021-01-012021-03-310001077183us-gaap:CustomerRelationshipsMembersrt:MinimumMember2021-01-012021-03-310001077183srt:MaximumMemberus-gaap:CustomerRelationshipsMember2021-01-012021-03-310001077183us-gaap:CustomerRelationshipsMember2021-03-310001077183us-gaap:TradeNamesMember2021-03-310001077183us-gaap:CustomerRelationshipsMembersrt:MinimumMember2020-01-012020-12-310001077183srt:MaximumMemberus-gaap:CustomerRelationshipsMember2020-01-012020-12-310001077183us-gaap:CustomerRelationshipsMember2020-12-310001077183us-gaap:TradeNamesMember2020-12-310001077183srt:AffiliatedEntityMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-05-220001077183srt:AffiliatedEntityMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-05-222020-05-220001077183srt:AffiliatedEntityMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberneo:PreferenceSharesMember2020-05-220001077183srt:AffiliatedEntityMemberneo:PurchaseOptionMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-05-220001077183us-gaap:MeasurementInputPriceVolatilityMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberneo:PreferenceSharesMember2021-01-012021-03-310001077183us-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberneo:PreferenceSharesMember2021-01-012021-03-310001077183us-gaap:MeasurementInputExpectedDividendRateMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberneo:PreferenceSharesMember2021-01-012021-03-310001077183neo:PurchaseOptionMemberus-gaap:MeasurementInputPriceVolatilityMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2021-01-012021-03-310001077183neo:PurchaseOptionMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2021-01-012021-03-310001077183us-gaap:MeasurementInputExpectedDividendRateMemberneo:PurchaseOptionMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2021-01-012021-03-310001077183us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-12-310001077183us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberneo:PreferenceSharesMember2020-12-310001077183neo:PurchaseOptionMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-12-310001077183us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-01-012020-12-310001077183neo:PurchaseOptionMemberus-gaap:MeasurementInputPriceVolatilityMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-01-012020-12-310001077183neo:PurchaseOptionMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-01-012020-12-310001077183us-gaap:MeasurementInputExpectedDividendRateMemberneo:PurchaseOptionMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-01-012020-12-310001077183us-gaap:LineOfCreditMembersrt:AffiliatedEntityMember2021-03-310001077183us-gaap:LineOfCreditMembersrt:AffiliatedEntityMember2021-01-012021-03-310001077183us-gaap:LineOfCreditMembersrt:AffiliatedEntityMember2021-01-310001077183us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberneo:PreferenceSharesMember2021-01-310001077183us-gaap:LineOfCreditMembersrt:AffiliatedEntityMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2021-01-012021-03-310001077183us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberneo:PreferenceSharesMember2021-01-012021-03-310001077183us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2021-03-310001077183us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberneo:PreferenceSharesMember2021-03-310001077183neo:PurchaseOptionMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2021-03-31utr:Rate0001077183neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMemberus-gaap:ConvertibleDebtMember2021-03-310001077183neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMemberus-gaap:ConvertibleDebtMember2020-12-310001077183us-gaap:ConvertibleDebtMemberneo:OnePointTwoFivePercentConvertibleSeniorNotesMember2020-12-310001077183neo:FinanceObligationsMember2021-03-310001077183neo:FinanceObligationsMember2020-12-310001077183neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleDebtMember2021-03-310001077183us-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleDebtMemberneo:OnePointTwoFivePercentConvertibleSeniorNotesMember2021-03-310001077183us-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleDebtMemberneo:OnePointTwoFivePercentConvertibleSeniorNotesMember2020-12-310001077183neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMemberus-gaap:ConvertibleDebtMember2021-01-110001077183us-gaap:OverAllotmentOptionMember2021-01-112021-01-11neo:day0001077183neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:ConvertibleDebtMember2021-01-112021-01-110001077183neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMemberus-gaap:ConvertibleDebtMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2021-01-112021-01-110001077183neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMemberus-gaap:ConvertibleDebtMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2021-01-110001077183neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMemberus-gaap:ConvertibleDebtMember2021-01-012021-03-310001077183neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMemberus-gaap:ConvertibleDebtMember2021-01-112021-01-110001077183neo:CappedCallTransactionsMember2021-01-112021-01-110001077183neo:CappedCallTransactionsMember2021-01-110001077183us-gaap:ConvertibleDebtMemberneo:OnePointTwoFivePercentConvertibleSeniorNotesMember2020-05-040001077183us-gaap:OverAllotmentOptionMember2020-05-042020-05-040001077183us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:ConvertibleDebtMemberneo:OnePointTwoFivePercentConvertibleSeniorNotesMember2020-05-042020-05-040001077183us-gaap:ConvertibleDebtMemberneo:OnePointTwoFivePercentConvertibleSeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2020-05-042020-05-040001077183us-gaap:ConvertibleDebtMemberneo:OnePointTwoFivePercentConvertibleSeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2020-05-040001077183us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:ConvertibleDebtMemberneo:OnePointTwoFivePercentConvertibleSeniorNotesMember2021-01-012021-03-310001077183us-gaap:ConvertibleDebtMemberneo:OnePointTwoFivePercentConvertibleSeniorNotesMember2020-05-042020-05-0400010771832020-05-042020-05-040001077183us-gaap:ConvertibleDebtMemberneo:OnePointTwoFivePercentConvertibleSeniorNotesMember2021-01-012021-03-310001077183neo:CommonStockOfferingMember2021-01-062021-01-060001077183neo:CommonStockOfferingMember2021-01-060001077183us-gaap:OverAllotmentOptionMember2021-01-062021-01-060001077183neo:CommonStockOfferingMember2020-04-292020-04-290001077183neo:CommonStockOfferingMember2020-04-290001077183us-gaap:OverAllotmentOptionMember2020-04-292020-04-290001077183us-gaap:OverAllotmentOptionMember2020-06-032020-06-030001077183srt:MinimumMember2021-01-012021-03-310001077183srt:MaximumMember2021-01-012021-03-310001077183us-gaap:RestrictedStockMember2020-12-310001077183us-gaap:RestrictedStockMember2021-01-012021-03-310001077183us-gaap:RestrictedStockMember2021-03-310001077183us-gaap:EmployeeStockMember2021-01-012021-03-310001077183us-gaap:EmployeeStockMember2020-01-012020-03-31neo:segment0001077183neo:ClientDirectBillingMemberneo:ClinicalServicesMember2021-01-012021-03-310001077183neo:ClientDirectBillingMemberneo:ClinicalServicesMember2020-01-012020-03-310001077183neo:CommercialInsuranceMemberneo:ClinicalServicesMember2021-01-012021-03-310001077183neo:CommercialInsuranceMemberneo:ClinicalServicesMember2020-01-012020-03-310001077183neo:MedicareAndOtherGovernmentalMemberneo:ClinicalServicesMember2021-01-012021-03-310001077183neo:MedicareAndOtherGovernmentalMemberneo:ClinicalServicesMember2020-01-012020-03-310001077183neo:SelfPayServicesMemberneo:ClinicalServicesMember2021-01-012021-03-310001077183neo:SelfPayServicesMemberneo:ClinicalServicesMember2020-01-012020-03-310001077183us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001077183us-gaap:EmployeeStockOptionMember2020-01-012020-03-310001077183us-gaap:RestrictedStockMember2021-01-012021-03-310001077183us-gaap:RestrictedStockMember2020-01-012020-03-310001077183neo:OnePointTwoFivePercentConvertibleSeniorNotesMemberus-gaap:ConvertibleDebtSecuritiesMember2021-01-012021-03-310001077183neo:OnePointTwoFivePercentConvertibleSeniorNotesMemberus-gaap:ConvertibleDebtSecuritiesMember2020-01-012020-03-310001077183neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMemberus-gaap:ConvertibleDebtSecuritiesMember2021-01-012021-03-310001077183neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMemberus-gaap:ConvertibleDebtSecuritiesMember2020-01-012020-03-310001077183neo:StrategicAllianceWithInivataLimitedMembersrt:AffiliatedEntityMember2021-01-012021-03-310001077183neo:StrategicAllianceWithInivataLimitedMembersrt:AffiliatedEntityMember2020-01-012020-03-310001077183us-gaap:SubsequentEventMemberneo:TrapeloHealthMember2021-04-072021-04-070001077183us-gaap:SubsequentEventMember2021-05-042021-05-040001077183us-gaap:PrivatePlacementMemberus-gaap:SubsequentEventMember2021-05-042021-05-040001077183us-gaap:PrivatePlacementMemberus-gaap:SubsequentEventMember2021-05-04


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to                   
Commission File Number: 001-35756
NEOGENOMICS, INC.
(Exact name of registrant as specified in its charter) 
Nevada 74-2897368
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
   
12701 Commonwealth Drive,Suite 9,Fort Myers, 
Florida 33913
(Address of principal executive offices) (Zip Code)
 
(239) 768-0600
(Registrant’s telephone number, including area code)
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common stock ($0.001 par value)NEOThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or ford such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  S No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  S   No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
S
Accelerated filer
Non-accelerated filerSmaller Reporting Company
 Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes     No  S
As of May 4, 2021, the registrant had 117,926,709 shares of Common Stock, par value $0.001 per share outstanding.




TABLE OF CONTENTS
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 




FORWARD-LOOKING STATEMENTS
The information in this Quarterly Report on Form 10-Q contains “forward-looking statements” and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the “Securities Act”, and Section 21E of the Securities Exchange Act of 1934, as amended, or the “Exchange Act”, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, changing reimbursement levels from government payers and private insurers, projected costs, prospects and plans and objectives of management. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that could cause our actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the risks set forth in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the “SEC”) on February 25, 2021.

Forward-looking statements include, but are not limited to, statements about:
Our ability to respond to rapid scientific change;
The risk of liability in conducting clinical trials and providing research services and the sufficiency of our insurance to cover such claims;
Our ability to implement our business strategy;
The anticipated impact to our business operations, customer demand and supply chain due to the recent global pandemic of a novel strain of the coronavirus;
The expected reimbursement levels from governmental payers and private insurers and proposed changes to those levels;
The application, to our business and the services we provide, of existing laws, rules and regulations, including without limitation, Medicare laws, anti-kickback laws, Health Insurance Portability and Accountability Act of 1996 regulations, state medical privacy laws, international privacy laws, federal and state false claims laws and corporate practice of medicine laws;
Regulatory developments in the United States including downward pressure on health care reimbursement;
Our ability to maintain our license under the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”);
Food and Drug Administration, or FDA regulation of Laboratory Developed Tests (“LDTs”);
Failure to timely or accurately bill for our services;
Our ability to expand our operations and increase our market share;
Our ability to expand our service offerings by adding new testing capabilities and overcome capacity constraints;
Our ability to develop or acquire licenses for new or improved testing technologies;
Our ability to meet our future capital requirements;
Our ability to manage our indebtedness;
Our ability to manage the quality of our investment portfolio;
Our expectations regarding the conversion of our outstanding 1.25% Convertible Senior Notes due May 2025 (the “2025 Convertible Notes”) or our outstanding 0.25% Convertible Senior Notes due January 2028 (the “2028 Convertible Notes”) in the aggregate principal amount of $201.3 million and $345 million, respectively, and our ability to make debt service payments under the 2025 Convertible Notes or 2028 Convertible Notes if such notes are not converted;
Our ability to protect our intellectual property from infringement;
Our ability to integrate future acquisitions and costs related to such acquisitions;
The effects of seasonality on our business;
Our ability to maintain service levels and compete with other diagnostic laboratories;
3


Our ability to hire and retain sufficient managerial, sales, clinical and other personnel to meet our needs;
Our ability to successfully scale our business, including expanding our facilities, our backup systems and infrastructure;
Our handling, storage and disposal of biological and hazardous materials;
The accuracy of our estimates regarding reimbursement, expenses, future revenues and capital requirements;
Our ability to manage expenses and risks associated with international operations, including anti-corruption and trade sanction laws and other regulations, and economic, political, legal and other operational risks associated with foreign jurisdictions;
Our ability to have sufficient cash to pay our obligations under the 2025 Convertible Notes or the 2028 Convertible Notes; and
The dilutive impact of the conversion of the 2025 Convertible Notes or the 2028 Convertible Notes.
Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time and it is not possible for management to predict all of such factors, nor can it assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.


4


PART I — FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
NEOGENOMICS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share amounts)
March 31, 2021 (unaudited)December 31, 2020
ASSETS
Current assets
Cash and cash equivalents$611,970 $228,713 
Marketable securities, at fair value190,710 67,546 
Accounts receivable, net102,922 106,843 
Inventories21,382 29,526 
Prepaid assets11,073 11,547 
Other current assets4,675 4,555 
Total current assets942,732 448,730 
Property and equipment (net of accumulated depreciation of $98,746 and $92,895, respectively)
94,315 85,873 
Operating lease right-of-use assets50,904 45,786 
Intangible assets, net118,195 120,653 
Goodwill211,083 211,083 
Restricted cash11,119 21,919 
Investment in non-consolidated affiliate29,555 29,555 
Loan receivable from non-consolidated affiliate10,185  
Prepaid lease asset21,052 20,229 
Other assets5,273 4,503 
Total non-current assets$551,681 $539,601 
Total assets$1,494,413 $988,331 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable$18,919 $24,965 
Accrued compensation23,621 24,727 
Accrued expenses and other liabilities14,018 11,654 
Current portion of equipment financing obligations2,089 2,841 
Current portion of operating lease liabilities5,111 4,967 
Pharma contract liabilities3,992 4,029 
Total current liabilities67,750 73,183 
Long-term liabilities
Convertible senior notes, net530,378 168,120 
Equipment financing obligations683 967 
Operating lease liabilities46,437 42,296 
Deferred income tax liabilities, net1,744 5,415 
Other long-term liabilities3,707 4,056 
Total long-term liabilities582,949 220,854 
     Total liabilities650,699 294,037 
Stockholders’ equity
Common stock, $0.001 par value, (250,000,000 shares authorized; 117,136,654 and 112,075,474 shares issued and outstanding, respectively)
117 112 
Additional paid-in capital872,350 701,357 
Accumulated other comprehensive (loss) income(150)10 
Accumulated deficit(28,603)(7,185)
     Total stockholders’ equity843,714 694,294 
     Total liabilities and stockholders' equity$1,494,413 $988,331 
See the accompanying notes to the unaudited Consolidated Financial Statements.
5


NEOGENOMICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)

 Three Months Ended March 31,
 20212020
NET REVENUE:  
Clinical Services$96,487 $92,982 
Pharma Services19,046 13,048 
Total revenue115,533 106,030 
COST OF REVENUE73,959 59,661 
GROSS PROFIT41,574 46,369 
Operating expenses:
General and administrative40,476 36,344 
Research and development2,456 2,060 
Sales and marketing13,749 13,258 
Total operating expenses56,681 51,662 
LOSS FROM OPERATIONS(15,107)(5,293)
Interest expense, net1,177 819 
Other expense (income), net4,854 (223)
Loss before taxes(21,138)(5,889)
Income tax expense976 1,089 
NET LOSS$(22,114)$(6,978)
NET LOSS PER SHARE
Basic$(0.19)$(0.07)
Diluted$(0.19)$(0.07)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic116,199 104,484 
Diluted116,199 104,484 

See the accompanying notes to the unaudited Consolidated Financial Statements.
6


NEOGENOMICS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(in thousands)
(unaudited)

Three Months Ended March 31,
20212020
NET LOSS$(22,114)$(6,978)
OTHER COMPREHENSIVE LOSS:
Net unrealized loss on marketable securities, net of tax(160) 
Unrealized loss on effective cash flow hedge, net of tax (1,038)
   Total other comprehensive loss, net of tax(160)(1,038)
COMPREHENSIVE LOSS$(22,274)$(8,016)

See the accompanying notes to the unaudited Consolidated Financial Statements.


7


NEOGENOMICS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(unaudited, in thousands, except share amounts)

Common StockAdditional Paid-In CapitalAccumulated Other Comprehensive (Loss) IncomeAccumulated DeficitTotal
Shares Amount
Balance, December 31, 2019104,781,236 $105 $520,278 $(1,618)$(11,357)$507,408 
Common stock issuance ESPP Plan34,330 — 796 — — 796 
Issuance of restricted stock, net of forfeitures76,618 — (212)— — (212)
Issuance of common stock for stock options503,873 — 2,897 — — 2,897 
Stock issuance fees and expenses— — (15)— — (15)
ESPP expense— — 194 — — 194 
Stock-based compensation expense - options and restricted stock— — 1,991 — — 1,991 
Unrealized loss on effective cash flow hedge, net of tax — — — (1,038)— (1,038)
Net loss— — — — (6,978)(6,978)
Balance, March 31, 2020105,396,057 $105 $525,929 $(2,656)$(18,335)$505,043 
Balance, December 31, 2020112,075,474 $112 $701,357 $10 $(7,185)$694,294 
Cumulative-effect adjustment from change in accounting principle— — (23,271)— 696 (22,575)
Premiums paid for capped call confirmations— — (29,291)— — (29,291)
Common stock issuance ESPP Plan23,917 — 1,024 — — 1,024 
Issuance of restricted stock, net of forfeitures83,220 — (614)— — (614)
Issuance of common stock for stock options260,167 — 2,239 — — 2,239 
Issuance of common stock - public offering, net of underwriting discounts4,693,876 5 218,495 — — 218,500 
Stock issuance fees and expenses— — (242)— — (242)
ESPP expense— — 241 — — 241 
Stock-based compensation expense - options and restricted stock— — 2,412 — — 2,412 
Net unrealized loss on marketable securities, net of tax— — — (160)— (160)
Net loss— — — — (22,114)(22,114)
Balance, March 31, 2021117,136,654 $117 $872,350 $(150)$(28,603)$843,714 
See the accompanying notes to the unaudited Consolidated Financial Statements.

8


NEOGENOMICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands) 
(unaudited) 
 Three Months Ended March 31,
20212020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss$(22,114)$(6,978)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation6,680 6,240 
Amortization of intangibles2,458 2,452 
Non-cash stock-based compensation2,653 2,186 
Non-cash operating lease expense1,862 2,021 
Amortization of convertible debt discount593  
Amortization of debt issue costs43 70 
Unrealized loss on investment in non-consolidated affiliate5,024  
Interest receivable on loan receivable from non-consolidated affiliate(209) 
Write-off of COVID-19 PCR testing inventory and equipment6,061  
Other non-cash items548 17 
Changes in assets and liabilities, net
Accounts receivable, net3,921 (5,722)
Inventories2,845 (5,348)
Prepaid lease asset(823)(3,316)
Prepaid and other assets(794)254 
Accounts payable, accrued and other liabilities(6,538)1,191 
Net cash provided by (used in) operating activities2,210 (6,933)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of marketable securities(137,776) 
Proceeds from sales and maturities of marketable securities13,919  
Purchases of property and equipment(15,831)(4,708)
Business acquisition (37,000)
Loan receivable from non-consolidated affiliate(15,000) 
Net cash used in investing activities(154,688)(41,708)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of equipment financing obligations(1,091)(1,598)
Repayment of term loan (1,250)
Issuance of common stock, net2,617 3,465 
Proceeds from issuance of convertible debt, net of issuance costs334,410  
Premiums paid for capped call confirmations(29,291) 
Proceeds from equity offering, net of issuance costs218,290  
Net cash provided by financing activities524,935 617 
Net change in cash, cash equivalents and restricted cash372,457 (48,024)
Cash, cash equivalents and restricted cash, beginning of period250,632 173,016 
Cash, cash equivalents and restricted cash, end of period$623,089 $124,992 

See the accompanying notes to the unaudited Consolidated Financial Statements.

9


Three Months Ended March 31,
20212020
Reconciliation of cash, cash equivalents and restricted cash to the Consolidated Balance Sheets:
   Cash and cash equivalents$611,970 $86,254 
   Restricted cash, non-current11,119 38,738 
Total cash, cash equivalents and restricted cash$623,089 $124,992 
Supplemental disclosure of cash flow information:
Interest paid$41 $1,136 
Income taxes (refunded) paid, net$(49)$2 
Supplemental disclosure of non-cash investing and financing information:
Property and equipment included in accounts payable$2,081 $1,844 

See the accompanying notes to the unaudited Consolidated Financial Statements.
10

NEOGENOMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

Note 1. Nature of the Business
Nature of the Business
NeoGenomics, Inc., a Nevada corporation, and its subsidiaries (the “Parent”, “Company”, or “NeoGenomics”), operates as a certified, high complexity clinical laboratory in accordance with the federal government’s CLIA, and is dedicated to the delivery of clinical diagnostic services to pathologists, oncologists, urologists, hospitals, and other laboratories as well as providing clinical trial services to pharmaceutical firms.
COVID-19 Pandemic Update
In December 2019, a novel strain of coronavirus (“COVID-19”) was identified and the disease has since spread across the world, including the United States (“U.S.”). In March 2020, the World Health Organization declared the outbreak of COVID-19 a pandemic. The outbreak of the pandemic is materially adversely affecting the Company’s employees, patients, communities and business operations, as well as the U.S. economy and financial markets. The full extent to which the COVID-19 outbreak will impact the Company’s business, results of operations, financial condition and cash flows will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets. As the COVID-19 pandemic continues, the Company’s results of operations, financial condition and cash flows are likely to continue to be materially adversely affected, particularly if the pandemic continues to persist for a significant amount of time.
The Company anticipates that the cash on hand, marketable securities and cash collections are sufficient to fund near-term capital and operating needs for at least the next 12 months.
At the end of the first quarter 2021, due to the broad roll-out of the COVID-19 vaccine and a sharp decline in COVID-19 polymerase chain reaction (“PCR”) testing demand, the Company made the decision to exit COVID-19 PCR testing and the Company recorded a $6.1 million expense related to the exit from COVID-19 PCR testing. This amount consisted of write-offs of $5.3 million for all remaining COVID-19 PCR testing inventory recorded to cost of revenue and $0.8 million for all remaining COVID-19 PCR testing laboratory equipment recorded to general and administrative expenses on the Consolidated Statements of Operations.
Coronavirus Aid, Relief and Economic Security Act
The Federal government passed legislation and the President of the United States signed into law on March 27, 2020, known as the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). On April 10, 2020, the U.S. Department of Health & Human Services announced that Medicare-enrolled providers would receive a portion of a direct deposit disbursement totaling $50 billion. The $50 billion is part of a $100 billion Public Health and Social Service Emergency Fund created by the CARES Act. Payments made under the CARES Act are intended to reimburse healthcare providers for health care related expenses or lost revenues attributable to COVID-19 and are not required to be repaid provided that recipients attest to and comply with certain terms and conditions, including limitations on balance billing for COVID-19 patients. In the absence of specific guidance to account for government grants in accordance with accounting principles generally accepted in the United States of America (“GAAP”), the Company accounts for such grants in accordance with international accounting standards for government grants. Such amounts are recognized when there is reasonable assurance that the Company will (1) comply with the conditions associated with the grant and (2) receive the grant.
The CARES Act permits the deferral of payment of the employer portion of social security taxes between March 27, 2020 and December 31, 2020, with 50% of the deferred amount due on December 31, 2021 and the remaining 50% due on December 31, 2022. As of March 31, 2021 and December 31, 2020 the total accrued deferred social security taxes, related to the CARES Act was $5.9 million. At both March 31, 2021 and December 31, 2020 this amount was recorded evenly between accrued expenses and other liabilities and other long-term liabilities on the Consolidated Balance Sheets.
Additionally, the CARES Act included an Employee Retention Tax Credit (“ERTC”) provision designed to encourage employers to keep employees on their payroll. The ERTC is a refundable tax credit against certain payroll taxes paid by employers for eligible wages paid between March 13, 2020 and December 31, 2020 that meet the requirements of the ERTC provision. On March 11, 2021, the American Rescue Plan Act was enacted extending the deadline of the ERTC to December 31, 2021 and expanded who is eligible to claim the credit. For the three months ended March 31, 2021, the Company recognized $0.4 million under the ERTC which was included in loss from operations on the Consolidated Statements of Operations. There were no such amounts recorded for the three months ended March 31, 2020.
11

NEOGENOMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

Note 2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying interim Consolidated Financial Statements are unaudited and have been prepared in accordance with GAAP for interim financial information. All intercompany transactions and balances have been eliminated in the accompanying Consolidated Financial Statements.
The accounting policies of the Company are the same as those set forth in Note 2. Summary of Significant Accounting Policies, to the audited Consolidated Financial Statements contained in the Company’s annual report on Form 10-K for the year ended December 31, 2020, except for Stock-Based Compensation, Income Taxes and the impact of the adoption of new accounting standards discussed under Recently Adopted Accounting Guidance.
Unaudited Interim Financial Information
Certain information and footnote disclosures normally included in the Company’s annual audited Consolidated Financial Statements and accompanying notes have been condensed or omitted in these accompanying interim consolidated financial statements and footnotes. Accordingly, the accompanying interim Consolidated Financial Statements included herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company’s annual report on Form 10-K for the year ended December 31, 2020.
The results of operations presented in this quarterly report on Form 10-Q are not necessarily indicative of the results of operations that may be expected for any future periods. In the opinion of management, these unaudited Consolidated Financial Statements include all adjustments and accruals, consisting only of normal, recurring adjustments that are necessary for a fair statement of the results of all interim periods reported herein.
Use of Estimates
The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management’s estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these Consolidated Financial Statements include, but are not limited to those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation and impairment analysis of goodwill. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.
Stock-Based Compensation
The Company measures compensation expense for stock-based awards to employees, non-employee contracted physicians, and directors based upon the awards’ initial grant-date fair value. The estimated grant-date fair value of the award is recognized as expense over the requisite service period using the straight-line method.
Prior to 2021, the Company estimated the fair value of stock options using a trinomial lattice model. On January 1, 2021, the Company began applying the Black-Scholes option valuation model (“Black-Scholes”) on a prospective basis to new awards. The Company expects the use of Black-Scholes to provide a more ubiquitous estimate of fair value. Like the prior trinomial lattice model, Black-Scholes is affected by the stock price on the date of the grant as well as assumptions regarding a number of highly complex and subjective variables. These variables include the expected term of the option, expected risk-free interest rate, the expected volatility of common stock, and expected dividend yield, each of which is more fully described below. The assumptions for expected term and expected volatility are the two assumptions that significantly affect the grant date fair value.
Expected Term: The expected term of an option is the period of time that the option is expected to be outstanding. The average expected term is determined using the Black-Scholes model.
Risk-free Interest Rate: The risk-free interest rate used in the Black-Scholes model is based on the implied yield at the grant date of the U.S. Treasury zero-coupon issue with an equivalent term to the stock-based award being valued. Where the expected term of a stock-based award does not correspond with the term for which a zero coupon interest rate is quoted, the Company uses the nearest interest rate from the available maturities.
Expected Stock Price Volatility: The Company uses its own historical weekly volatility because that is more reflective of market conditions.
Dividend Yield: Because the Company has never paid a dividend and does not expect to begin doing so in the foreseeable future, the Company assumed no dividend yield in valuing the stock-based awards.
12

NEOGENOMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

Income Taxes
Deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different depreciation methods and lives for property and equipment, recognition of accounts receivable, compensation related expenses, and various other expenses that have been allowed for or accrued for financial statement purposes but are not currently deductible for income tax purposes.
The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized.
Management assesses the recoverability of its deferred tax assets as of the end of each quarter, weighing available positive and negative evidence, and is required to establish and maintain a valuation allowance for these assets if it is more likely than not that some or all of the deferred income tax assets will not be realized. The weight given to the evidence is commensurate with the extent to which the evidence can be objectively verified. If negative evidence exists, positive evidence is necessary to support a conclusion that a valuation allowance is not needed.
As of December 31, 2020, expected future reversals of the Company’s deferred income tax liabilities provided objectively verifiable positive evidence to support the recoverability of its deferred tax assets. However, on January 1, 2021, the Company adopted ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) - Accounting For Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) using the modified retrospective approach, which resulted in a decrease of approximately $6.6 million in the Company’s deferred income tax liabilities. In addition, approximately $2 million of valuation allowance against the Company’s deferred income tax assets was established upon adoption of ASU 2020-06, resulting from the decrease in deferred income tax liabilities available to support the recoverability of deferred tax assets. The valuation allowance represents the portion of the Company’s U.S. deferred income tax assets that are not more likely than not to be realized in future periods, primarily related to Federal and California research and development tax credit carryforwards.
A cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome. Cumulative loss in recent years is commonly defined as a three-year cumulative loss position. As of March 31, 2021, the Company’s U.S. operations were in a three-year cumulative loss position. Management determined that sufficient objectively verifiable positive evidence did not exist to overcome the negative evidence of the Company’s U.S. cumulative loss position. Accordingly, the Company’s estimated annual effective tax rate applied to the Company’s pre-tax loss for the three months ended March 31, 2021 included the unfavorable impact of valuation allowance expected to be established against the Company’s deferred income tax assets expected to be created in 2021 for additional the U.S. net operating loss and tax credit carryforwards.
As of March 31, 2021, the Company’s total valuation allowance against U.S. deferred income tax assets was approximately $9.3 million. The Company also continued to maintain a full valuation allowance against deferred tax assets in Switzerland, Singapore and China, which increased from $2.6 million as of December 31, 2020 to $3 million as of March 31, 2021.
The Company evaluates tax positions that have been taken or are expected to be taken in its tax returns, and records a liability for uncertain tax positions, if deemed necessary. The Company follows a two-step approach to recognizing and measuring uncertain tax positions. First, tax positions are recognized if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon examination, including resolution of related appeals or litigation processes, if any. Second, the tax position is measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon settlement.
The Company recognizes interest and penalties related to unrecognized tax benefits in the provision for income taxes in the accompanying Consolidated Balance Sheets. At March 31, 2021 and December 31, 2020 the Company had an uncertain tax position related to Federal and State R&D tax credit carryforwards, including a provision for interest and penalties related to such position. No interest and penalties have been accrued, as the income tax credits are carried forward to offset income tax liabilities in future years.
Recently Adopted Accounting Guidance
In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements, which updates various codification topics by clarifying disclosure requirements to align with the SEC's regulations. The Company adopted this pronouncement on January 1, 2021 and the impact of the provisions of this standard on its Consolidated Financial Statements was immaterial.
13

NEOGENOMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) - Accounting For Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entitys own equity. Among other changes, ASU 2020-06 simplifies the accounting for convertible instruments by removing the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such convertible debt instruments. Similarly, the debt discount, that is equal to the carrying value of the embedded conversion feature upon issuance, will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible instrument was issued at a substantial premium. In addition, ASU 2020-06 requires the application of the if-converted method for calculating the impact of convertible instruments on diluted earnings per share. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. ASU 2020-06 can be adopted on either a fully retrospective or modified retrospective basis.
The Company adopted ASU 2020-06 on January 1, 2021 using the modified retrospective approach, and accordingly the Company recorded an adjustment that reflects the 1.25% Convertible Senior Notes due 2025 as if the embedded conversion feature had not been separated. The impact upon adoption on the Consolidated Balance Sheets included an increase of approximately $27.2 million in convertible senior notes, net, a write-off of approximately $6.6 million in deferred income tax liabilities, establishment of approximately $2 million of valuation allowance against deferred income tax assets, and a decrease of approximately $23.3 million in additional paid-in capital. In addition, upon adoption, there was an adjustment to increase the beginning balance of retained earnings on the Consolidated Balance Sheets for previously recognized interest expense, net of tax effects, of approximately $2.7 million for amortization of debt discount related to the carrying value of the embedded conversion feature upon issuance, as well as a decrease to the beginning balance of retained earnings of approximately $2 million for the establishment of valuation allowance against the Company's deferred income tax assets. There was no impact to the Companys earnings per share calculation. See Note 7. Debt for further information regarding the 1.25% Convertible Senior Notes due 2025.
In January 2020, the FASB issued ASU No. 2020-01, Investments-Equity Securities (“Topic 321”), Investments-Equity Method and Joint Ventures (“Topic 323”) and Derivatives and Hedging (“Topic 815”) (collectively, ASU 2020-01). ASU 2020-01 clarifies the interaction of the accounting for equity securities under Topic 321, the accounting for the equity method investments in Topic 323 and the accounting for certain forward contracts and purchased options in Topic 815. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020 on a prospective basis and early adoption was permitted. The Company adopted ASU 2020-01 on January 1, 2021 and there was no impact from the provisions of this standard on its Consolidated Financial Statements.
In December 2019, the FASB issued ASU No. 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes (“Topic 740”), which simplifies the accounting for income taxes, eliminates certain exceptions within Topic 740 and clarifies certain other aspects of the current guidance to promote consistency among reporting entities. The new standard is effective for fiscal years beginning after December 15, 2020 on a prospective basis and early adoption is permitted. The Company adopted this pronouncement on January 1, 2021 and the impact of the provisions of this standard on its Consolidated Financial Statements was immaterial.
Accounting Pronouncements Pending Adoption
In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (ASU 2020-04) which provides for temporary optional expedients and exceptions to the current guidance on certain contract modifications and hedging relationships to ease the burdens related to the expected market transition from the London Inter-bank Offered Rate (LIBOR) or other reference rates to alternative reference rates. In January 2021, the FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848) (ASU 2021-01) to clarify that certain optional expedients and exceptions apply to modifications of derivative contracts and certain hedging relationships affected by changes in the interest rates used for discounting cash flows, computing variation margin settlements, and for calculating price alignment interest. ASU 2020-04 is effective beginning on March 12, 2020 and may be applied prospectively to such transactions through December 31, 2022 and ASU 2021-01 is effective beginning on January 7, 2021 and may be applied retrospectively or prospectively to such transactions through December 31, 2022. The Company will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. As of March 31, 2021, there was no impact to the Company’s Consolidated Financial Statements related to ASU 2020-04 or ASU 2021-01.
14

NEOGENOMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

Note 3. Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy has been established based on three levels of inputs, of which the first two are considered observable and the last unobservable.
Level 1: Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.
Level 2: Inputs, other than quoted prices included within Level 1, which are observable for the asset or liability, either directly or indirectly. These are typically obtained from readily-available pricing sources for comparable instruments.
Level 3: Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own assumptions of the data that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.
Assets and Liabilities that are Measured at Fair Value on a Recurring Basis
The Company measures certain financial assets at fair value on a recurring basis, including its marketable securities and certain cash equivalents. The Company considers all securities available-for-sale, including those with maturity dates beyond 12 months, and therefore these securities are classified within current assets on the consolidated balance sheets as they are available to support current operational liquidity needs. The money market accounts are valued based on quoted market prices in active markets. The marketable securities are generally valued based on other observable inputs for those securities (including market corroborated pricing or other models that utilize observable inputs such as interest rates and yield curves) based on information provided by independent third-party pricing entities, except for U.S. Treasury securities which are valued based on quoted market prices in active markets.
The following tables set forth the amortized cost, gross unrealized gains, gross unrealized losses and fair values of the Company’s marketable securities accounted for as available-for-sale securities as of March 31, 2021 and December 31, 2020.

March 31, 2021
(in thousands)Amortized CostGross Unrealized GainsGross Unrealized LossesFair Value
Financial Assets:
Short-term marketable securities:
     U.S. Treasury securities$51,745 $1 $(43)$51,703 
     Commercial paper22,187   22,187 
     Asset-backed securities21,612  (15)21,597 
     Corporate bonds95,371  (148)95,223 
Total$190,915 $1 $(206)$190,710 

December 31, 2020
(in thousands)Amortized CostGross Unrealized GainsGross Unrealized LossesFair Value
Financial Assets:
Short-term marketable securities:
     U.S. Treasury securities$21,357 $1 $(18)$21,340 
     Commercial paper14,543   14,543 
     Asset-backed securities14,546  (8)14,538 
     Corporate bonds17,144  (19)17,125 
Total$67,590 $1 $(45)$67,546 



15

NEOGENOMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)



The Company had $0.5 million and $0.2 million of accrued interest receivable at March 31, 2021 and December 31, 2020, respectively, included in other current assets on its Consolidated Balance Sheets related to its marketable securities. Realized gains or losses on marketable securities for the three months ended March 31, 2021 were immaterial. There were no realized gains or losses on marketable securities for the three months ended March 31, 2020.
The following tables set forth the fair value of available-for-sale marketable securities by contractual maturity at March 31, 2021 and December 31, 2020.
March 31, 2021
(in thousands)One Year or LessOver One Year Through Five YearsOver Five YearsTotal
Financial Assets:
Marketable Securities:
     U.S. Treasury securities$9,113 $42,590 $ $51,703 
     Commercial paper22,187   22,187 
     Asset-backed securities451 21,146  21,597 
     Corporate bonds23,282 71,941  95,223 
Total$55,033 $135,677 $ $190,710 

December 31, 2020
(in thousands)One Year or LessOver One Year Through Five YearsOver Five YearsTotal
Financial Assets:
Marketable Securities:
     U.S. Treasury securities$6,075 $15,265 $ $21,340 
     Commercial paper14,543   14,543 
     Asset-backed securities560 13,978  14,538 
     Corporate bonds5,863 11,262  17,125 
Total$27,041 $40,505 $ $67,546 

The following tables set forth the Company’s cash equivalents and marketable securities accounted for as available-for-sale securities that were measured at fair value on a recurring basis based on the fair value hierarchy as of March 31, 2021 and December 31, 2020.
March 31, 2021
(in thousands)Level 1Level 2Level 3Total
Financial Assets:
  Cash equivalents:
     Money market funds$570,782 $ $ $570,782 
     Commercial paper 17,795  17,795 
Marketable securities:
     U.S. Treasury securities51,703   51,703 
     Commercial paper 22,187  22,187 
     Asset-backed securities 21,597  21,597 
     Corporate bonds 95,223  95,223 
Total$622,485 $156,802 $ $779,287 

16

NEOGENOMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

December 31, 2020
(in thousands)Level 1Level 2Level 3Total
Financial Assets:
  Cash equivalents:
     Money market funds$209,141 $ $ $209,141 
     U.S. Treasury securities1,000   1,000 
     Commercial paper 3,999  3,999 
Marketable securities:
     U.S. Treasury securities21,340   21,340 
     Commercial paper 14,543  14,543 
     Asset-backed securities 14,538  14,538 
     Corporate bonds — 17,125  17,125 
Total$231,481 $50,205 $ $281,686 

There were no transfers of financial assets or liabilities into or out of Level 1, Level 2, or Level 3 for the three months ended March 31, 2021 and March 31, 2020.
Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis
The carrying value of cash and cash equivalents, accounts receivable, net, accounts payable, accrued expenses and other liabilities, and other current assets and liabilities, are considered reasonable estimates of their respective fair values at March 31, 2021 and December 31, 2020 due to their short-term nature.
The Company also measures certain non-financial assets at fair value on a nonrecurring basis, primarily intangible assets, goodwill, and long-lived assets in connection with periodic evaluations for potential impairment. The Company estimates the fair value of these assets using primarily unobservable inputs and, as such, these are considered Level 3 fair value measurements.
17

NEOGENOMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

Note 4. Leases
As of March 31, 2021, the maturities of our operating lease liabilities and a reconciliation to the present value of lease liabilities were as follows (in thousands):

Remaining Lease Payments
Remainder of 2021$5,480 
20227,150 
20237,071 
20247,179 
20254,381 
Thereafter34,230 
Total remaining lease payments65,491 
Less: imputed interest(13,943)
Total operating lease liabilities51,548 
Less: current portion(5,111)
Long-term operating lease liabilities$46,437 
Weighted-average remaining lease term (in years)10.95
Weighted-average discount rate4.2 %
The following summarizes additional supplemental data related to operating leases (in thousands):

Three Months Ended March 31,
20212020
Operating lease costs$2,305 $2,105 

Three Months Ended March 31,
20212020
Right-of-use assets obtained in exchange for operating lease liabilities$6,580 $24,071 
Cash paid for operating leases$2,678 $1,553 

Lease contracts that have been executed but have not yet commenced are excluded from the tables above. As of March 31, 2021 the Company has entered into $33.8 million of contractually binding minimum lease payments for leases executed but not yet commenced. This amount primarily relates to the lease of the laboratory and headquarters facility in Fort Myers, Florida that is expected to commence in 2021. In addition to the minimum lease payments, the Company will pay approximately $25 million relating to the construction of the underlying assets and approximately $17 million in leasehold improvements. These amounts were placed into separate construction disbursement escrow accounts and as of March 31, 2021, $11.1 million was unpaid and remaining in restricted cash on the Consolidated Balance Sheets. Disbursements to the landlord take place from time to time to pay for the costs of the landlord’s work. The disbursements are classified as a prepaid lease asset or leasehold improvements, as appropriate, until the lease commences. Upon lease commencement, the prepaid lease asset will be included in the calculation of the right-of-use asset and the leasehold improvements will be placed in service. Construction of the infrastructure of this facility commenced in the first quarter of 2020. The Company is not expected to control the underlying assets during the construction period and therefore is not considered the owner of the underlying assets for accounting purposes.
Note 5. Goodwill and Intangible Assets
Goodwill as of March 31, 2021 and December 31, 2020 was $211.1 million. There was no change in the carrying amount of goodwill during the three months ended March 31, 2021.
Intangible assets consisted of the following as of (in thousands): 
18

NEOGENOMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

  March 31, 2021
 Amortization
Period
CostAccumulated
Amortization
Net
Customer Relationships
84-180 months
$143,101 $38,353 $104,748 
Trade Name - Indefinite lived— 13,447 — 13,447 
Total $156,548 $38,353 $118,195 
 
  December 31, 2020
 Amortization
Period
CostAccumulated
Amortization
Net
Customer Relationships
84 - 180 months
$143,101 $35,895 $107,206 
Trade Name - Indefinite lived— 13,447 — 13,447 
Total$156,548 $35,895 $120,653 
 
The Company recorded approximately $2.5 million straight-line amortization expense of intangible assets for each of the three months ended March 31, 2021 and 2020. The Company records amortization expense within general and administrative expense on the Consolidated Statement of Operations.
The estimated amortization expense related to amortizable intangible assets for each of the four succeeding fiscal years and thereafter as of March 31, 2021 is as follows (in thousands):
 
Remainder of 2021$7,373 
20229,832 
20239,832 
20249,832 
20259,832 
Thereafter58,047 
Total$104,748 
 
19

NEOGENOMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

Note 6. Investment in Non-Consolidated Affiliate
On May 22, 2020, the Company formed a strategic alliance with Inivata Limited, a company incorporated in England and Wales (“Inivata”), and entered into a Strategic Alliance Agreement and Laboratory Services Agreement with Inivata's laboratory subsidiary in the U.S., Inivata, Inc., whereas Inivata’s laboratory will render and perform certain laboratory testing which the Company will make available to customers. The terms and conditions of the Laboratory Services Agreement are consistent with those that would be negotiated between willing parties on an arm’s length basis. See Note 12. Related Party Transactions, for additional details on amounts paid related to the Laboratory Services Agreement.
In addition to the Laboratory Services Agreement, the Company also entered into an Investment Agreement with Inivata (the “Investment Agreement”), pursuant to which the Company acquired Series C1 Preference Shares (the “Preference Shares”) for $25 million in cash (the “Investment”) resulting in a minority interest in Inivata’s outstanding equity and an Option Deed which provides the Company with an option to purchase Inivata (the “Purchase Option”). The Investment Agreement also granted the Company one seat on Inivata’s Board of Directors.
Inivata is a VIE and the Company’s investment is under 20% of the total equity outstanding. The Company considers qualitative factors in assessing the primary beneficiary of the VIE which include understanding the purpose and design of the VIE, associated risks that the VIE creates, activities that could be directed by the Company, and the expected relative impact of those activities on the economic performance of the VIE. Based on an evaluation of these factors, the Company concluded that it is not the primary beneficiary of Inivata.
The power to control the activities that most significantly impact Inivata’s economic performance are the sole responsibility of Inivata’s management and Board of Directors; however, the Company does have significant influence over Inivata. As the Preference Shares were determined to not be in-substance common stock, and because the Preference Shares and the Purchase Option do not have readily determinable fair values, the Company has elected to measure the Preference Shares and the Purchase Option at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
On May 22, 2020, the initial $25 million cost and $0.6 million of associated transaction costs for the Investment was allocated between the Preference Shares and the Purchase Option based on the relative fair value of each and was recorded as investment in non-consolidated affiliate on the Consolidated Balance Sheets. The initial relative fair value of the investment in non-consolidated affiliate was comprised of $19.6 million in Preference Shares and a $6 million Purchase Option. The Preference Shares were valued by determining the equity value of Inivata using the Backsolve Method and allocating the value of the Preference Shares using the Option-Pricing Method and the inputs used included the equity value based on the Series C1 capital raised by Inivata, a volatility rate of 84%, a risk-free interest rate of 0.17% and 0% dividend yield. The Purchase Option was valued using the Black-Scholes model with a volatility rate of 84%, a risk-free interest rate of 0.17% and 0% dividend yield.
During the fourth quarter of 2020, an observable transaction of an identical investment in Inivata Preference Shares occurred. This resulted in a remeasurement of the Preference Shares to the value of this observable transaction. The Purchase Option was also remeasured at fair value as a result of this observable transaction. As a result of these remeasurements, at December 31, 2020, the carrying value of the investment in non-consolidated affiliate was $29.6 million, comprised of $25 million in Preference Shares and a $4.6 million Purchase Option. The Company recorded a net unrealized gain of $4 million for these remeasurements for the year ended December 31, 2020 in other expense (income), net on the Consolidated Statements of Operations. At December 31, 2020, the Purchase Option was valued using the Black-Scholes model with a volatility rate of 84%, a risk-free interest rate of 0.17% and 0% dividend yield.
On May 22, 2020, the Company and Inivata also entered into a line of credit agreement in the amount of $15 million (the “Line of Credit”). In January 2021, the Line of Credit, in its entirety, was drawn by Inivata and recorded as a loan receivable from non-consolidated affiliate on the Consolidated Balance Sheets. The Line of Credit matures on December 1, 2025 and the unpaid principal balance is payable on January 1, 2026. The Line of Credit bears interest at 0% per annum. In January 2021, upon the draw of the Line of Credit by Inivata, the Company used an imputed interest rate of 8.33% to present value the Line of Credit. The Company recorded an imputed interest rate discount of $5 million on the loan receivable from non-consolidated affiliate and an additional investment in non-consolidated affiliate of $5 million, resulting in a $10 million present value of the loan receivable from non-consolidated affiliate and increasing the value of the Preference Shares to $30 million. For the three months ended March 31, 2021, $0.2 million of interest income was amortized to the loan receivable from non-consolidated affiliate. The interest income was recorded in interest expense, net, on the Consolidated Statements of Operations. As of March 31, 2021, the loan receivable from non-consolidated affiliate, net of discount, was $10.2 million on the Consolidated Balance Sheets.
In the first quarter of 2021, subsequent to Inivata's draw on the Line of Credit, an observable transaction of an identical investment in Inivata Preference Shares occurred. This resulted in a remeasurement of the Preference Shares to the value of this observable transaction. The Company recorded a net unrealized loss of $5 million for this remeasurement for the three months
20

NEOGENOMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

ended March 31, 2021 in other expense (income), net on the Consolidated Statements of Operations. As of March 31, 2021, the carrying value of the investment in non-consolidated affiliate is $29.6 million, comprised of $25 million in Preference Shares and a $4.6 million Purchase Option.
The Line of Credit is subject to evaluation for current expected credit losses. The impact of such losses were determined to be immaterial at March 31, 2021. There were no such amounts recorded on the Consolidated Balance Sheets as of December 31, 2020.
At March 31, 2021, the maximum exposure to losses does not exceed the carrying amount of the investment in non-consolidated affiliate combined with the carrying amount of the loan receivable from non-consolidated affiliate.
21

NEOGENOMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

Note 7. Debt
The following table summarizes the long-term debt, net at March 31, 2021 and December 31, 2020 (in thousands):
 March 31, 2021December 31, 2020
0.25% Convertible Senior Notes due 2028
Principal$345,000 $ 
Unamortized debt discount(10,049) 
Unamortized debt issuance costs(233) 
Total 0.25% Convertible Senior Notes due 2028
$334,718 $ 
1.25% Convertible Senior Notes due 2025
Principal$201,250 $201,250 
Unamortized debt discount(4,974)(32,592)
Unamortized debt issuance costs(616)(538)
Total 1.25% Convertible Senior Notes due 2025
$195,660 $168,120 
Equipment financing obligations2,772 3,808 
Total debt$533,150 $171,928 
Less: Current portion of financing obligations(2,089)(2,841)
Total long-term debt, net$531,061 $169,087 
 
At March 31, 2021, the estimated fair values (Level 2) of the 0.25% Convertible Senior Notes due 2028 and the 1.25% Convertible Senior Notes due 2025 were $301.7 million and $339.2 million, respectively. There was no such estimated fair value as of December 31, 2020 related to the 0.25% Convertible Senior Notes due 2028. At December 31, 2020, the estimated fair value (Level 2) of the 1.25% Convertible Senior Notes due 2025 was $320.9 million. At March 31, 2021 and December 31, 2020, the carrying value of the Company’s equipment financing obligations approximated fair value based on the current market conditions for similar instruments.
2028 Convertible Senior Notes
On January 11, 2021, the Company completed the sale of $345 million of Convertible Senior Notes with a stated interest rate of 0.25% and a maturity date of January 15, 2028 (the “2028 Convertible Notes”), unless earlier converted, redeemed, or repurchased. The 2028 Convertible Notes were issued at a discounted price of 97% of their principal amount. The total net proceeds from the issuance of the 2028 Convertible Notes and exercise of the Over-allotment Option was approximately $334.4 million, which includes approximately $10.6 million of discounts, commissions and offering expenses paid by the Company. On January 11, 2021 the Company entered into an Indenture (the “Indenture”), with U.S. Bank National Association, as trustee (the “Trustee”), governing the 2028 Convertible Notes. The Company used a portion of the net proceeds from the Offerings to enter into capped call transactions (as described below under the heading “Capped Call Transactions”).
Prior to September 15, 2027, noteholders may convert their 2028 Convertible Notes at their option, only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021 (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of 2028 Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; (3) if the Company calls any or all of the notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after September 15, 2027 until the close of business on the second business day immediately preceding the maturity date, noteholders may convert their 2028 Convertible Notes at any time, regardless of the foregoing circumstances.
Upon conversion, the Company will pay or deliver, as applicable, cash, shares of common stock or a combination of cash and shares of common stock, at its election. The initial conversion rate for the 2028 Convertible Notes is 15.1172 shares of common stock per $1,000 in principal amount of 2028 Convertible Notes, equivalent to an initial conversion price of approximately $66.15 per share of common stock. The conversion rate is subject to adjustment as described in the Indenture. In addition,
22

NEOGENOMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

following certain corporate events that occur prior to the maturity date as described in the Indenture, the Company will pay a make-whole premium by increasing the conversion rate for a holder who elects to convert its 2028 Convertible Notes in connection with such a corporate event in certain circumstances. The value of the 2028 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $48.23 on March 31, 2021. For the three months ended March 31, 2021 the Company excluded 4,867,738 shares in diluted weighted average common shares outstanding for the if-converted impact of the 2028 Convertible Notes from the diluted net loss per share calculation as the shares would have an anti-dilutive effect. For further details on the impact of the 2028 Convertible Notes on net loss per share please refer to Note 11. Net Loss Per Share.
The Company may not redeem the 2028 Convertible Notes prior to January 20, 2025. The Company may redeem for cash all or any portion of the 2028 Convertible Notes, at its option, on or after January 20, 2025 if the last reported sale price of its common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date of notice by the Company of redemption at a redemption price equal to 100% of the principal amount of the 2028 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2028 Convertible Notes.
If an event involving bankruptcy, insolvency or reorganization events with respect to the Company occurs, then the principal amount of, and all accrued and unpaid interest on, all of the 2028 Convertible Notes then outstanding will immediately become due and payable. If any other default event occurs and is continuing, then noteholders of at least 25% of the aggregate principal amount of the 2028 Convertible Notes then outstanding, by notice to the Company, may declare the principal amount of, and all accrued and unpaid interest on, all of the 2028 Convertible Notes then outstanding to become due and payable immediately. If the Company undergoes a “fundamental change” as defined in the Indenture, then noteholders may require the Company to repurchase their 2028 Convertible Notes at a cash repurchase price equal to the principal amount of the 2028 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.
The 2028 Convertible Notes are the Company’s senior, unsecured obligations and will be equal in right of payment with its existing and future senior, unsecured indebtedness, senior in right of payment to its existing and future indebtedness that is expressly subordinated to the 2028 Convertible Notes and effectively junior to its existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness. The 2028 Convertible Notes will be structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, of its subsidiaries.
The interest expense recognized on the 2028 Convertible Notes includes $0.2 million, $0.4 million and $6,700 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended March 31, 2021. There were no such amounts for the three months ended March 31, 2020. The effective interest rate on the 2028 Convertible Notes is 0.70%, which includes the interest on the 2028 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2028 Convertible Notes bear interest at a rate of 0.25% per annum, payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2021.
Capped Call Transactions
In connection with the 2028 Convertible Notes offering, on January 11, 2021, the Company entered into separate, privately negotiated convertible note hedge transactions (collectively, the “Capped Call Transactions”) with option counterparties pursuant to capped call confirmations at a cost of approximately $29.3 million. As the Capped Call Transactions meet certain accounting criteria, the Capped Call Transactions were classified as equity, are not accounted for as derivatives and were recorded as a reduction of the Company’s additional paid-in capital in the accompanying Consolidated Financial Statements. The Capped Call Transactions are not part of the terms of the 2028 Convertible Notes and will not affect any holders’ rights under the 2028 Convertible Notes. The Capped Call Transactions cover, subject to customary anti-dilution adjustments, the number of shares of the Company’s common stock that initially underlie the 2028 Convertible Notes. The number of shares underlying the Capped Call Transactions is 5.2 million.
The cap price of the Capped Call Transactions is initially $85.75 per share of the Company's common stock, which represents a premium of 75% over the public offering price of the common stock in the 2021 Common Stock Offering, which was $49.00 per share, and is subject to certain adjustments under the terms of the Capped Call Transactions.
By entering into the Capped Call Transactions, the Company expects to reduce the potential dilution to its common stock (or, in the event a conversion of the 2028 Convertible Notes is settled in cash, to reduce its cash payment obligation) in the event that, at the time of conversion of the 2028 Convertible Notes, its common stock price exceeds the conversion price of the 2028 Convertible Notes.
2025 Convertible Senior Notes
23

NEOGENOMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

On May 4, 2020, the Company completed the sale of $201.3 million of Convertible Senior Notes with a stated interest rate of 1.25% and a maturity date of May 1, 2025 (the “2025 Convertible Notes”), unless earlier converted, redeemed, or repurchased. The 2025 Convertible Notes were issued at a discounted price of 97% of their principal amount. The total net proceeds from the issuance of the 2025 Convertible Notes and exercise of the Over-allotment Option was approximately $194.5 million, which includes approximately $6.9 million of discounts, commissions and offering expenses paid by the Company. On May 4, 2020, the Company entered into an Indenture (the “Indenture”), with U.S. Bank National Association, as trustee (the “Trustee”), governing the 2025 Convertible Notes.
Prior to February 1, 2025, noteholders may convert their 2025 Convertible Notes at their option, only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2020 (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of 2025 Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; (3) if the Company calls any or all of the notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after February 1, 2025 until the close of business on the business day immediately preceding the maturity date, noteholders may convert their 2025 Convertible Notes at any time, regardless of the foregoing circumstances.
The last reported sales price of the Company’s common stock was greater than or equal to 130% of the conversion price of the 2025 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarters ended March 31, 2021 and December 31, 2020. Based on the terms of the 2025 Convertible Notes, the holders may convert all or a portion of their 2025 Convertible Notes in the second quarter of 2021 and could have converted all or a portion of their 2025 Convertible Notes in the first quarter of 2021. When a conversion notice is received, the Company has the option to pay or deliver cash, shares of the Company’s common stock, or a combination thereof. As the Company is not required to settle the 2025 Convertible Notes in cash, the 2025 Convertible Notes are classified as long-term debt as of March 31, 2021 and December 31, 2020. As of March 31, 2021, the Company had not received any conversion notices.
Upon conversion, the Company will pay or deliver, as applicable, cash, shares of common stock or a combination of cash and shares of common stock, at its election. The initial conversion rate for the 2025 Convertible Notes is 27.5198 shares of common stock per $1,000 in principal amounts of 2025 Convertible Notes, equivalent to an initial conversion price of approximately $36.34 per share of common stock. The conversion rate is subject to adjustment as described in the Indenture. In addition, following certain corporate events that occur prior to the maturity date as described in the Indenture, the Company will pay a make-whole premium by increasing the conversion rate for a holder who elects to convert its 2025 Convertible Notes in connection with such a corporate event in certain circumstances. The value of the 2025 Convertible Notes, if-converted, exceeds the principal amount by $65.9 million based on a closing stock price of $48.23 on March 31, 2021. For the three months ended March 31, 2021 the Company excluded 5,538,360 shares in diluted weighted average common shares outstanding for the if-converted impact of the 2025 Convertible Notes from the diluted net loss per share calculation as the shares would have an anti-dilutive effect. For further details on the impact of the 2025 Convertible Notes on net loss per share please refer to Note 11. Net Loss Per Share.
The Company may not redeem the 2025 Convertible Notes prior to May 6, 2023. The Company may redeem for cash all or any portion of the 2025 Convertible Notes, at its option, on or after May 6, 2023 if the last reported sale price of its common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date of notice by the Company of redemption at a redemption price equal to